Final answer:
For neuroleptic malignant syndrome that doesn't respond to supportive care, 'a) Bromocriptine' and 'b) Dantrolene' are the typical pharmacological treatments used to alleviate the syndrome's symptoms.
Step-by-step explanation:
The treatment for neuroleptic malignant syndrome (NMS), if a patient doesn't respond to supportive care, primarily includes the use of dopaminergic agents like bromocriptine or dantrolene, which are often used to help manage symptoms. Specifically, the typical choices are:
- Bromocriptine - A dopamine agonist that can mimic the effects of dopamine in the brain and provide symptomatic relief.
- Dantrolene - A muscle relaxant that acts on skeletal muscle fibers to reduce muscle rigidity and metabolic abnormalities associated with NMS.
Therefore, the correct answer to the question is 'a) Bromocriptine' and 'b) Dantrolene'. Both agents are part of the primary line of treatment when supportive care is not sufficient. Levodopa and amantadine are generally used in the treatment of Parkinson's disease but are not the first line of treatment for NMS.